By Fineline Cube 
Trinomab Biotechnology Co., Ltd. (SHA: 688806) officially listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange under stock code 688806. Founded in 2015, the company is pioneering alternative therapies for plasma-derived products through innovative monoclonal antibody development.
IPO Details
| Item | Detail |
|---|---|
| Exchange | Shanghai Stock Exchange – STAR Market |
| Stock Code | 688806 |
| Listing Date | July 21, 2026 |
| Company Focus | Alternative therapies to plasma-derived products |
| Founded | 2015 |
Product Portfolio & Pipeline
Siltartoxatug – Commercialized Asset
- Status: Approved for marketing by China’s National Medical Products Administration (NMPA)
- Innovation: World’s first-in-class fully human anti-tetanus monoclonal antibody
- Significance: Represents a plasma-free alternative to traditional tetanus immunoglobulin derived from human plasma
- Commercial Stage: First commercialized core product generating revenue
TNM001 – Late-Stage Pipeline Candidate
- Status: New Drug Application (NDA) submitted with Priority Review status granted in China
- Target: Respiratory syncytial virus (RSV)
- Technology: Recombinant long-acting fully human monoclonal antibody
- Development Stage: Awaiting regulatory decision following priority review designation
Strategic Differentiation
Trinomab’s platform addresses critical limitations of plasma-derived therapies, which face challenges including:
- Supply constraints due to dependence on human plasma donations
- Batch-to-batch variability in product quality
- Risk of blood-borne pathogen transmission
- Limited scalability for global distribution
The company’s fully human monoclonal antibody approach offers consistent quality, scalable manufacturing, and enhanced safety profiles compared to traditional plasma-derived alternatives.
Market Opportunity
The global market for tetanus prophylaxis and RSV therapeutics represents significant commercial potential:
- Tetanus: Annual global demand for tetanus immunoglobulin exceeds 1 million doses
- RSV: Affects approximately 33 million children annually worldwide, with limited treatment options
- Plasma Alternatives: Growing regulatory and clinical preference for recombinant over plasma-derived products
Investment Thesis
Trinomab’s dual-pronged strategy combines near-term revenue generation from its approved anti-tetanus antibody with high-value pipeline potential in the RSV therapeutic market. The company’s focus on first-in-class monoclonal antibodies positions it as a leader in the plasma-alternative therapeutic category.
Company Background
Since its founding in 2015, Trinomab has built a specialized expertise in monoclonal antibody development targeting infectious disease indications traditionally addressed with plasma-derived products. The company’s listing on the STAR Market provides capital to accelerate commercialization and advance its pipeline.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, commercial performance, and market opportunities. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market adoption.-Fineline Info & Tech